Abviva receives Japanese patent for Mammastatin Serum Assay Abviva.

Abviva receives Japanese patent for Mammastatin Serum Assay Abviva, Inc. , a biomedical firm engaged in the development and commercialization of breasts cancer related applications of Mammastatin, announced today that japan Patent Office released two patents on the core technology which may be used for therapeutic applications and in the business’s breast cancer risk assessment test, the Mammastatin Serum Assay . The patents are the most recent of 13 worldwide and U eriacta .S. Patents to issue to the University of Michigan for breast malignancy therapeutic and diagnostic uses of Mammastatin. ‘Not merely will these patent grants enable us to penetrate japan market with proprietary technology, they further validate, along with earlier patent grants covering 16 European countries, Canada, Australia, and america, the global patentability of the Mammastatin technology.’ The MSA was initially created at the University of Michigan Cancers Middle and is licensed specifically to Abviva by the University for scientific and commercial development as a bloodstream test to assess women’s wellness.

Academy calls for research intend to minimize environmental influence of Marcellus Shale gas drilling Researchers propose comprehensive analysis plan to understand the environmental influence of drillingThe Academy of Organic Sciences is calling for a comprehensive research plan that would result in guidelines and an assessment device for regulators and managers in order to minimize the environmental effect of Marcellus Shale gas drilling. At the moment, there is very little information available as to the impacts of long-term exposure of a watershed to Marcellus Shale drilling activities, said Dr. David Velinsky, vice president of the Academy’s Patrick Middle for Environmental Study. Nor do we know when there is a cumulative influence of drilling activity on the ecosystem solutions of a small watershed.